How Consultants Make Strategy Happen

Why It Matters

By converting high‑impact genomics research into a phased, partnership‑driven business plan, companies can unlock commercial value faster and secure the financing needed for large‑scale health innovations.

Key Takeaways

• Align scientific ambition with decision‑grade strategic choices across organization.
• Anchor strategy on unique population genomics capabilities at scale.
• Prioritize actionable science, separating it from exploratory research.
• Create phased roadmap using data, clinical utility, reimbursement.
• Form partnerships to accelerate drug discovery and clinical trials.

Summary

The video explains how consultants translate a biotech firm’s scientific ambition into a concrete, decision‑grade strategy. By working directly with the CFO, CEO, chief genetics officer, and chief medical officer, they bridge the gap between cutting‑edge genomics research and executable business plans, focusing on population genomics at scale and its fastest‑moving clinical pathways—screening, monitoring, diagnostics, and prevention.

Key insights include anchoring the strategy on the company’s unique strength in large‑scale population genomics, separating “true” science from what can be acted upon today, and building a phased roadmap driven by data, clinical utility, reimbursement prospects, and integration into care pathways. The consultants also stress the importance of strategic partnerships to fuel future drug discovery and trial programs.

Notable statements from the discussion highlight the methodology: “We anchored the strategy on what this player can do uniquely well, which is population genomics at scale,” and “We separated the science that’s true from the science that’s actionable now.” These quotes illustrate the practical split between long‑term research and immediate market‑ready applications.

The implications are clear: a disciplined, data‑backed approach enables biotech firms to prioritize investments, accelerate time‑to‑market, and attract external partners, ultimately turning scientific potential into sustainable revenue streams and competitive advantage.

Original Description

How do you turn ambition into real outcomes?

Elsy M. Dumit, MPH from Roland Berger breaks it down: Partner → Prioritize → Deliver.

🎥 Highlight from the Life Sciences Consulting Panel

Watch the full panel discussion on the Management Consulted YouTube channel: https://www.youtube.com/watch?v=PbgEaZlphI4

#managementconsulted #lifesciences #thoughtpartner #client #strategy #csuite #rolandberger

Subscribe to our channel: https://www.youtube.com/@Managementconsulted?sub_confirmation=1

Additional Resources

⚑ Learn how to use Excel and PowerPoint like a consultant with this course: https://managementconsulted.com/excel-powerpoint/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

⚑ Get 1:1 Power Presentations Coaching to become a Trusted Advisor in your organization: https://managementconsulted.com/power-presentation/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

⚑ Learn how Executive Communication Training could increase your team's influence: https://managementconsulted.com/storytelling/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

Subscribe to our channel: https://www.youtube.com/@Managementconsulted?sub_confirmation=1